Anacetrapib, a novel CETP inhibitor: Pursuing a new approach to cardiovascular risk reduction

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 109-122

  Gutstein, D E ^a   Krishna, R ^a   Johns, D ^a   Surks, H K ^a   Dansky, H M ^a   Shah, S ^a   Mitchel, Y B ^a   Arena, J ^a   Wagner, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; DIGOXIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB; WARFARIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; HEPATITIS; HUMAN; MOLECULAR MECHANICS; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS AS TOPIC; HUMANS; OXAZOLIDINONES; RISK REDUCTION BEHAVIOR;

EID: 84055207675     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.271     Document Type: Review

References (92)

1. Baigent, C.et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
2. Smith, C.J.et al. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. J. Med. Chem. 54, 4880-4895 (2011).
3. Heron, M., Hoyert, D.L., Murphy, S.L., Xu, J., Kochanek, K.D. & Tejada-Vera, B. Deaths: final data for 2006. Natl. Vital Stat. Rep. 57, 1-134 (2009).
4. A merican Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2008 Update 〈http://circ. ahajournals.org/content/117/4/e25.full〉 (2008).
5. World Health Organization. The top 10 causes of death 〈http://www.who.int/mediacentre/factsheets/fs310/en/index.html〉.
6. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002).
7. Canou-Poitrine, F. et al.; PRIME Study Group. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc. Dis. 30, 252-259 (2010).
8. Di Angelantonio, E. et al.; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993-2000 (2009).
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
10. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
11. Deedwania, P. et al.; Treating to New Targets Investigators. Reduction of lowdensity lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919-928 (2006). (Pubitemid 44331360)
12. Chapman, M.J. et al.; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345-1361 (2011).
13. Bursill, C.A. et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 30, 1773-1778 (2010).
14. Mineo, C., Deguchi, H., Griffin, J.H. & Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 98, 1352-1364 (2006). (Pubitemid 43948059)
15. Rye, K.A., Bursill, C.A., Lambert, G., Tabet, F. & Barter, P.J. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (suppl.), S195-S200 (2009).
16. Khera, A.V. & Rader, D.J. Future therapeutic directions in reverse cholesterol transport. Curr. Atheroscler. Rep. 12, 73-81 (2010).
17. Tall, A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263, 256-273 (2008). (Pubitemid 351207349)
18. Khera, A.V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
19. Gordon, D.J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989). (Pubitemid 19043669)
20. Bruckert, E., Labreuche, J. & Amarenco, P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361 (2010).
21. The AMI-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. (2011); e-pub ahead of print 15 November 2011.
22. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE 〈http://clinicaltrials.gov/ct2/show/NCT00461630〉.
23. Jun, M. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875-1884 (2010).
24. Ginsberg, H.N. et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
25. Keech, A. et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
26. Duffy, D. & Rader, D.J. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113, 1140-1150 (2006).
27. Shah, P.K. Emerging HDL-based therapies for atherothrombotic vascular disease. Curr. Treat. Options Cardiovasc. Med. 9, 60-70 (2007). (Pubitemid 46578390)
28. Kontush, A. Cholesteryl ester transfer protein (CETP) inhibitors and their role in cardiovascular disorders. Drugs Fut. 36, 377-384 (2011).
29. Barter, P.J. et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007). (Pubitemid 350146106)
30. Robinson, J.G. Dalcetrapib: a review of phase II data. Expert Opin. Investig. Drugs 19, 795-805 (2010).
31. Stein, E.A., Roth, E.M., Rhyne, J.M., Burgess, T., Kallend, D. & Robinson, J.G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur. Heart J. 31, 480-488 (2010).
32. A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome 〈http://clinicaltrials.gov/ct2/show/ NCT00658515〉.
33. Barter, P.J., Hopkins, G.J. & Calvert, G.D. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J. 208, 1-7 (1982). (Pubitemid 13215389)
34. Barter, P.J., Brewer, H.B. Jr, Chapman, M.J., Hennekens, C.H., Rader, D.J. & Tall, A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167 (2003). (Pubitemid 36231923)
35. Gu?in, M., Le Goff, W., Lassel, T.S., Van Tol, A., Steiner, G. & Chapman, M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21, 282-288 (2001). (Pubitemid 32125379)
36. de Grooth, G.J. et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173, 261-267 (2004). (Pubitemid 38469794)
37. McPherson, R. et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 11, 797-804 (1991).
38. Moulin, P., Appel, G.B., Ginsberg, H.N. & Tall, A.R. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J. Lipid Res. 33, 1817-1822 (1992). (Pubitemid 23006658)
39. Brown, M.L. et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-451 (1989). (Pubitemid 19277523)
40. Inazu, A. et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990). (Pubitemid 20366528)
41. Boekholdt, S.M., Kuivenhoven, J.A., Hovingh, G.K., Jukema, J.W., Kastelein, J.J. & van Tol, A. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr. Opin. Lipidol. 15, 393-398 (2004). (Pubitemid 39061618)
42. Keebler, M.E., Sanders, C.L., Surti, A., Guiducci, C., Burtt, N.P. & Kathiresan, S. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III. Circ. Cardiovasc. Genet. 2, 238-243 (2009).
43. Thompson, A. et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299, 2777-2788 (2008). (Pubitemid 351846853)
44. Boekholdt, S.M. & Thompson, J.F. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J. Lipid Res. 44, 1080-1093 (2003). (Pubitemid 37279626)
45. Ridker, P.M., Par-G., Parker, A.N., Zee, R.Y., Miletich, J.P. & Chasman, D.I. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2, 26-33 (2009).
46. Zhong, S. et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923 (1996). (Pubitemid 26197108)
47. Curb, J.D. et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45, 948-953 (2004). (Pubitemid 38552866)
48. Clark, R.W., Ruggeri, R.B., Cunningham, D. & Bamberger, M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537-552 (2006). (Pubitemid 43345595)
49. Ranalletta, M. et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51, 2739-2752 (2010).
50. Clark, R.W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004). (Pubitemid 38326143)
51. Cunningham, D. et al. Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein. Bioconjug. Chem. 19, 1604-1613 (2008).
52. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K. & Shinkai, H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207 (2000). (Pubitemid 30469005)
53. Niesor, E.J. et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-?-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51, 3443-3454 (2010).
54. Niesor, E.J. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr. Opin. Lipidol. 22, 288-295 (2011).
55. Sugano, M. et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273, 5033-5036 (1998). (Pubitemid 28108660)
56. Rittershaus, C.W. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 2106-2112 (2000).
57. Morehouse, L.A. et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48, 1263-1272 (2007). (Pubitemid 47312028)
58. Castro-Perez, J. et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52, 1965-1973 (2011).
59. Y van-Charvet, L. et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30, 1430-1438 (2010).
60. Y amashita, S., Sprecher, D.L., Sakai, N., Matsuzawa, Y., Tarui, S. & Hui, D.Y. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J. Clin. Invest. 86, 688-695 (1990). (Pubitemid 20327355)
61. Y van-Charvet, L. et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27, 1132-1138 (2007). (Pubitemid 46641969)
62. Ikewaki, K. et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96, 1573-1581 (1995).
63. Millar, J.S. et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26, 1350-1356 (2006). (Pubitemid 44305381)
64. Davidson, M.H., McKenney, J.M., Shear, C.L. & Revkin, J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48, 1774-1781 (2006). (Pubitemid 44648633)
65. McKenney, J.M., Davidson, M.H., Shear, C.L. & Revkin, J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48, 1782-1790 (2006). (Pubitemid 44648632)
66. Funder, J.W. Aldosterone, sodium, and hypertension: lessons from torcetrapib? Hypertension 55, 221-223 (2010).
67. DePasquale M. et al. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors. Drug Dev. Res. 70, 35-48 (2009).
68. Forrest, M.J. et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154, 1465-1473 (2008).
69. Polakowski, J.S. et al. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. J. Cardiovasc. Pharmacol. 54, 543-551 (2009).
70. Stroes, E.S. et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br. J. Pharmacol. 158, 1763-1770 (2009).
71. Derks, M., Anzures-Cabrera, J., Turnbull, L. & Phelan, M. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Clin. Drug Investig. 31, 325-335 (2011).
72. Blasi, E. et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J. Cardiovasc. Pharmacol. 53, 507-516 (2009).
73. Krishna, R. et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84, 679-683 (2008).
74. Krishna, R. et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370, 1907-1914 (2007). (Pubitemid 350192656)
75. Tan, E.Y. et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab. Dispos. 38, 459-473 (2010).
76. Kumar, S. et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab. Dispos. 38, 474-483 (2010).
77. Krishna, R. et al. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J. Clin. Pharmacol. 49, 80-87 (2009).
78. Dalvie, D. et al. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab. Dispos. 36, 2185-2198 (2008).
79. Prakash, C. et al. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab. Dispos. 36, 2064-2079 (2008).
80. Kuhlmann, O. & Heinig, K. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica. 41, 430-436 (2011).
81. Derks, M., Busse-Reid, R., Kuhlmann, O. & Paehler, A. [14C]-Dalcetrapib ADME following a single oral dose in healthy male subjects. Clin Pharmacol Ther 87, S37 (abstr.) (2010).
82. Sanderson, J.P., Naisbitt, D.J. & Park, B.K. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 8, E55-E64 (2006). (Pubitemid 44603864)
83. Garg, A.et al. Effect of diltiazem a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects. J. Clin. Pharmacol. 51, 436-439 (2011).
84. Krishna, R.et al. Effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. 112th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Dallas, TX, 2-5 March 2011
85. Krishna, R. et al. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects. Biopharm. Drug. Dispos. (2011): e-pub ahead of print 26 October 2011.
86. Krishna, R. et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 68, 535-545 (2009).
87. Bloomfield, D. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157, 352-360.e2 (2009).
88. Clarke, R. et al.; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
89. Krishna, R., Bergman, A.J., Green, M., Dockendorf, M.F., Wagner, J.A. & Dykstra, K. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. AAPS J. 13, 179-190 (2011).
90. Cannon, C.P. et al.; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406-2415 (2010).
91. Cannon, C.P. et al.; DEFINE investigators. Design of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Am. Heart J. 158, 513-519.e3 (2009).
92. Krishna, R. & Wagner, J.A. Applications of "decisionable" biomarkers in cardiovascular drug development. Biomark. Med. 4, 815-827 (2010).